Business Wire

Bledsoe Telephone Cooperative Selects Nominum to Deliver a Faster, More Secure Internet

Del

Nominum™, the DNS-based security and services innovation leader, announced today that Bledsoe Telephone Cooperative, which provides phone, broadband internet and IPTV services to subscribers in Tennessee, has deployed the company’s industry-leading Vantio™ CacheServe DNS software to improve speed, security and reliability of its broadband network. Additionally, Bledsoe will use Nominum N2™ ThreatAvert and N2 Secure Consumer to protect both its network and broadband subscribers from malicious cyberattacks like DDoS, phishing, ransomware and other malware.

Bledsoe turned to Nominum to speed up DNS query resolution and ensure thorough safeguards are in place to keep malicious threats from slowing or otherwise negatively impacting performance of its network. With the increasing frequency and severity of cyberthreats impacting service provider networks and their customers, Bledsoe will also deploy Nominum N2 ThreatAvert to thwart DDoS, DNS amplification and Pseudo Random Subdomain (PRSD) attacks.

The telecom operator is also implementing Nominum N2 Secure Consumer to keep subscribers protected from phishing, ransomware and other cyberthreats across all devices and networks, while providing parental control features that enable subscribers to set policies to block inappropriate content and limit time spent online for their children.

“Our previous DNS solution delivered slow response times and lacked the strong security capabilities we now have with Nominum, which resulted in a less than optimal experience for our subscribers,” said Russ Camp, CIO for Bledsoe. “Our goal was to maximize network reliability through the most cost-effective means possible. With Nominum, we have seen a significant difference with consistently better performance and assurance that our network is protected from cyberattacks and hackers. Support call volume has gone down and reliability has gone up—both of which strengthen our brand and generate greater customer loyalty.”

“The combination of Nominum Vantio CacheServe DNS software with the N2 application suite enables service providers to deliver a ‘closed loop’ security experience for their subscribers, from ensuring optimal performance of the network, to protecting the network from DNS-based attacks, to securing subscribers and their devices, to notifications and remediation when a breach has occurred,” said Daniel Blasingame, Vice President of Sales, North America for Nominum. “Operators like Bledsoe recognize the need for ever-greater cyber protections and a scalable network infrastructure given the major growth taking place with adoption of IoT devices and consumers’ increasingly mobile lifestyle. As a partner in their success, our mission is to enable a better, safer and faster internet for their subscribers—and for internet users everywhere.”

Nominum Vantio and N2: Creating a Stronger, Faster and More Secure Internet

The Nominum N2 product suite is designed to optimize and secure consumer and business users’ online activities through robust DNS-based network protection, subscriber/device security and personalized notifications when a breach occurs—delivering a closed loop security experience. Through the combination of Nominum’s industry-leading Vantio CacheServe unified DNS platform and N2, ISPs strengthen their competitive advantage, accelerate revenue growth and increase brand loyalty. The full product suite includes:

  • Vantio CacheServe—Offers high network availability and low latency for ISP networks.
  • N2 ThreatAvert—Proactively protects ISP networks from cyberthreats with accurate, adaptive and automated technology.
  • N2 Secure Consumer—Provides consumers with personalized internet safety solutions such as parental controls, and proactively protects households from malware, ransomware and phishing attacks.
  • N2 Secure Business—Security as a Service solution enabling ISPs to easily deploy SMB and enterprise cyberthreat protection to prevent ransomware, phishing, botnets and zero-day malware attacks.
  • N2 Reach—In-browser subscriber communications and campaign management platform that is proven to be more effective than email, direct mail, phone calls or text.

About Nominum

Nominum™ is a pioneer and global leader in DNS-based security and services innovation. The Silicon Valley company provides an integrated suite of carrier-grade DNS-based solutions that enable fixed and mobile operators to protect and enhance their networks, strengthen security for business and residential subscribers and offer innovative value-added services that can be monetized. The result is improved service agility, higher ARPU, increased brand loyalty and a strong competitive advantage. More than 130 service providers in over 40 countries trust Nominum to deliver a safe, customizable internet and promote greater value to over half a billion users. Nominum DNS software resolves 1.7 trillion queries around the globe every day—roughly 100 times more transactions than the combined daily volume of tweets, likes, and searches taking place on major web properties. For more information visit nominum.com.

Follow us on Twitter: @nominum https://twitter.com/nominum

Follow us on LinkedIn: https://www.linkedin.com/company/nominum

See us on YouTube: https://www.youtube.com/nominum

Read our latest blogs: http://nominum.com/blog/ | http://nominum.com/tech-blog/

Contact information

Nominum
Nancy MacGregor, +1-415-309-5185
PR Director
nancy.macgregor@nominum.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01Pressemelding

Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a

Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®19.11.2017 22:21Pressemelding

Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercial

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31Pressemelding

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom